Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer

Neoplasia

Volumn 10, Issue 11, 2008, Pages 1285-1294

  Varambally, Sooryanarayana ^a   Laxman, Bharathi ^a   Mehra, Rohit ^a   Cao, Qi ^a   Dhanasekaran, Saravana M ^a   Tomlins, Scott A ^a   Granger, Jill ^a   Vellaichamy, Adaikkalam ^a   Sreekumar, Arun ^a   Yu, Jianjun ^b   Gu, Wenjuan ^b   Shen, Ronglai ^b   Ghosh, Debashis ^b   Wright, Lorinda M ^c,d   Kladney, Raleigh D ^e   Kuefer, Rainer ^f   Rubin, Mark A ^g   Fimmel, Claus J ^c,d   Chinnaiyan, Arul M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d LOYOLA UNIVERSITY CHICAGO   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF ULM   (Germany)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GOLGI MEMBRANE PROTEIN 1; MEMBRANE PROTEIN; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOPSY TECHNIQUE; CANCER CELL CULTURE; CANCER DIAGNOSIS; CELLULAR DISTRIBUTION; COHORT ANALYSIS; CONTROLLED STUDY; CYTOPLASM; EMBRYO; GENE EXPRESSION; GOLGI COMPLEX; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LASER CAPTURE MICRODISSECTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATECTOMY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAINING; SUPERNATANT; UPREGULATION; URINE; URINE LEVEL; URINE SEDIMENT; VALIDATION STUDY;

EID: 55849106651     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.08922     Document Type: Article

References (40)

1. Abate-Shen C and Shen MM (2000). Molecular genetics of prostate cancer. Genes Dev 14, 2410-2434.
2. Gronberg H (2003). Prostate cancer epidemiology. Lancet 361, 859-864.
3. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, and Chinnaiyan AM (2001). Delineation of prognostic biomarkers in prostate cancer. Nature 412, 822-826.
4. Emmert-Buck MR, Gillespie JW, Paweletz CP, Ornstein DK, Basrur V, Appella E, Wang QH, Huang J, Hu N, Taylor P, et al. (2000). An approach to proteomic analysis of human tumors. Mol Carcinog 27, 158-165.
5. Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, Sanda MG, Pienta KJ, Ghosh D, and Chinnaiyan AM (2002). alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 287, 1662-1670.
6. Rubin MA, Varambally S, Beroukhim R, Tomlins SA, Rhodes DR, Paris PL, Hofer MD, Storz-Schweizer M, Kuefer R, Fletcher JA, et al. (2004). Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer. Cancer Res 64, 3814-3822.
7. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, et al. (2005). Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644-648.
8. Mertz KD, Setlur SR, Dhanasekaran SM, Demichelis F, Perner S, Tomlins S, Tchinda J, Laxman B, Vessella RL, Beroukhim R, et al. (2007). Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. Neoplasia 9, 200-206.
9. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, et al. (2002). The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624-629.
10. Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE, Cao Q, Prensner JR, Rubin MA, Shah RB, et al. (2008). Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10, 177-188.
11. Menschikowski M, Hagelgans A, Gussakovsky E, Kostka H, Paley EL, and Siegert G (2008). Differential expression of secretory phospholipases A2 in normal and malignant prostate cell lines: regulation by cytokines, cell signaling pathways, and epigenetic mechanisms. Neoplasia 10, 279-286.
12. Dong Z, Saliganan AD, Meng H, Nabha SM, Sabbota AL, Sheng S, Bonfil RD, and Cher ML (2008). Prostate cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover. Neoplasia 10, 439-449.
13. Rogers CG, Yan G, Zha S, Gonzalgo ML, Isaacs WB, Luo J, De Marzo AM, Nelson WG, and Pavlovich CP (2004). Prostate cancer detection on urinalysis for alpha methylacyl coenzyme a racemase protein. J Urol 172, 1501-1503.
14. Sreekumar A, Laxman B, Rhodes DR, Bhagavathula S, Harwood J, Giacherio D, Ghosh D, Sanda MG, Rubin MA, and Chinnaiyan AM (2004). Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer. J Natl Cancer Inst 96, 834-843.
15. Kladney RD, Bulla GA, Guo L, Mason AL, Tollefson AE, Simon DJ, Koutoubi Z, and Fimmel CJ (2000). GP73, a novel Golgi-localized protein upregulated by viral infection. Gene 249, 53-65.
16. Bachert C, Fimmel C, and Linstedt AD (2007). Endosomal trafficking and proprotein convertase cleavage of cis Golgi protein GP73 produces marker for hepatocellular carcinoma. Traffic (Copenhagen, Denmark) 8, 1415-1423.
17. Marrero JA, Romano PR, Nikolaeva O, Steel L, Mehta A, Fimmel CJ, Comunale MA, D'Amelio A, Lok AS, and Block TM (2005). GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol 43, 1007-1012.
18. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, et al. (2004). Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 101, 811-816.
19. Laxman B, Morris DS, Yu J, Siddiqui J, Cao J, Mehra R, Lonigro RJ, Tsodikov A, Wei JT, Tomlins SA, et al. (2008). A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res 68, 645-649.
20. Strous GJ, van Kerkhof P, van Meer G, Rijnboutt S, and Stoorvogel W (1993). Differential effects of brefeldin A on transport of secretory and lysosomal proteins. J Biol Chem 268, 2341-2347.
21. Ivessa NE, Gravotta D, De Lemos-Chiarandini C, and Kreibich G (1997). Functional protein prenylation is required for the brefeldin A-dependent retrograde transport from the Golgi apparatus to the endoplasmic reticulum. J Biol Chem 272, 20828-20834.
22. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, et al. (2003). EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 100, 11606-11611.
23. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, and Speleman F (2002). Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3, RESEARCH 0034.
24. Laxman B, Tomlins SA, Mehra R, Morris DS, Wang L, Helgeson BE, Shah RB, Rubin MA, Wei JT, and Chinnaiyan AM (2006). Noninvasive detection of TMPRSS2: ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia 8, 885-888.
25. Specht K, Richter T, Muller U, Walch A, Werner M, and Hofler H (2001). Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. Am J Pathol 158, 419-429.
26. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, Kalyana-Sundaram S, Wei JT, Rubin MA, Pienta KJ, et al. (2007). Integrative molecular concept modeling of prostate cancer progression. Nat Genet 39, 41-51.
27. Manley S, Mucci NR, De Marzo AM, and Rubin MA (2001). Relational database structure to manage high-density tissue microarray data and images for pathology studies focusing on clinical outcome: the prostate specialized program of research excellence model. Am J Pathol 159, 837-843.
28. Mehra R, Varambally S, Ding L, Shen R, Sabel MS, Ghosh D, Chinnaiyan AM, and Kleer CG (2005). Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. Cancer Res 65, 11259-11264.
29. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, and Chinnaiyan AM (2004). ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6, 1-6.
30. Chandran UR, Ma C, Dhir R, Bisceglia M, Lyons-Weiler M, Liang W, Michalopoulos G, Becich M, and Monzon FA (2007). Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer 7, 64.
31. Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B, Kiemeney LA, Witjes JA, and Schalken JA (2003). DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 44, 8-15; discussion 15-16.
32. Johnstone RM (2006). Exosomes biological significance: a concise review. Blood Cells Mol Dis 36, 315-321.
33. MacKenzie A, Wilson HL, Kiss-Toth E, Dower SK, North RA, and Surprenant A (2001). Rapid secretion of interleukin-1beta by microvesicle shedding. Immunity 15, 825-835.
34. Lu Y, Yi Y, Liu P, Wen W, James M, Wang D, and You M (2007). Common human cancer genes discovered by integrated gene-expression analysis. PLoS ONE 2, e1149.
35. Kladney RD, Tollefson AE, Wold WS, and Fimmel CJ (2002). Upregulation of the Golgi protein GP73 by adenovirus infection requires the E1A CtBP interaction domain. Virology 301, 236-246.
36. Moggs JG, Tinwell H, Spurway T, Chang HS, Pate I, Lim FL, Moore DJ, Soames A, Stuckey R, Currie R, et al. (2004). Phenotypic anchoring of gene expression changes during estrogen-induced uterine growth. Environ Health Perspect 112, 1589-1606.
37. Coleman IM, Kiefer JA, Brown LG, Pitts TE, Nelson PS, Brubaker KD, Vessella RL, and Corey E (2006). Inhibition of androgen-independent prostate cancer by estrogenic compounds is associated with increased expression of immune-related genes. Neoplasia 8, 862-878.
38. Wei S, Dunn TA, Isaacs WB, De Marzo AM, and Luo J (2008). GOLPH2 and MYO6: putative prostate cancer markers localized to the Golgi apparatus. Prostate 68, 1387-1395.
39. Wright LM, Yong S, Picken MM, Rockey D, and Fimmel CJ (2009). Decreased survival and hepato-renal pathology in mice with C-terminally truncated GP73 (GOLPH2). Int J Clin Exp Pathol 2, 34-47.
40. Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ, et al. (2005). Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 8, 393-406.